Passer au contenu principal
Centre intégré universitaire de santé
et de services sociaux de l'Est-de-l'Île-de-Montréal

Centre intégré universitaire de santé et de services sociaux de l'Est-de-l'Île-de-Montréal

Richard LeBlanc, M.D.

Richard LeBlanc

Hémato-oncologue, Professeur titulaire

L'équipe de l’IHOT

Chercheur-clinicien

Contact

Tél. : 514 252-3404

Dr Richard LeBlanc se spécialise dans tous les aspects liés au myélome multiple, qu’il s’agisse de formation, de soins, de recherche clinique ou encore de la gestion de la Banque de cellules myélomateuse affiliée à la Banque de cellules leucémiques du Québec.

 

  • Membre du Comité de priorisation clinique et recherche de l'IHOT
  • Titulaire de la Chaire Myélome Canada de l'Université de Montréal
  • Entrée en poste à l’Hôpital Maisonneuve-Rosemont : 2009

 

Formation :

  • Fellowship en myélome multiple et immunologie : Dana-Farber Cancer Institute de la Harvard Medical School, Boston (États-Unis), 2000-2002
  • Résidences en médecine interne, hématologie et oncologie médicale : Université Laval et Université de Montréal (Canada), 1995-2004
  • Doctorat en médecine : Université Laval, Québec (Canada), 1991-1995
     

Découvrez ses publications

  • Poor outcome despite modern treatments: A retrospective study of 99 patients with primary and secondary plasma cell leukemia

    Camille Tessier , Richard LeBlanc , Jean Roy , Sabrina Trudel, Julie Côté, Marc Lalancette, Jean-Samuel Boudreault, Émilie Lemieux-Blanchard, Rayan Kaedbey, Michel Pavic
    DOI 10.1002/cam4.70192 PMID 39225552
    Consulter

  • Long-term follow-up of outcomes including progression-free survival 2 in patients with transplant-ineligible multiple myeloma in the real-world practice: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) database

    Rayan Kaedbey, Donna Reece, Christopher P. Venner, Arleigh McCurdy, Jiandong Su, Michael Chu, Martha Louzada, Victor H Jimenez‐Zepeda, Hira Mian, Kevin Song, Michael Sebag, Julie Stakiw, Darrell White , Anthony Reiman, Muhammad Aslam, Rami Kotb, Debra Bergstrom, Engin Gul , Richard LeBlanc
    DOI 10.1002/jha2.894 PMID 38895063
    Consulter

  • Real world data on outcomes of anti-CD38 antibody treated, including triple class refractory, patients with multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

    A. Visram, A. De La Torre, D. White, J. Su, E. Masih-Khan, M. Chu, V. Jimenez-Zepeda, A. McCurdy , Richard LeBlanc , K. Song, H. Mian, M. Louzada, M. Sebag, D. Bergstrom, J. Stakiw, A. Reiman, R. Kotb, M. Aslam, C. Venner, R. Kaedbey, E. Gul, D. Reece
    DOI 10.1038/s41408-023-00946-z PMID 38065967
    Consulter

  • Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies

    Gary J Schiller, Brea C Lipe, Nizar J Bahlis, Sascha A Tuchma, William I Bensinger, Heather J Sutherland, Suzanne Lentzsch, Muhamed Baljevic, Darrell White, Rami Kotb, Christine I Chen, Adriana Rossi, Noa Biran , Richard LeBlanc , Sebastian Grosicki, Maurizio Martelli, Eberhard Gunsilius, Ivan Špička, Don Ambrose Stevens, Thierry Facon, Mercedes Gironella Mesa, Chris Zhang, Dane R Van Domelen, Ohad S Bentur, Cristina Gasparetto
    DOI 10.1016/j.clml.2023.06.001 PMID 37393120
    Consulter

  • Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma

    Amélie Giguère, Isabelle Raymond-Bouchard, Vanessa Collin , Jean-Sébastien Claveau , Josée Hébert , Richard LeBlanc
    DOI 10.3390/cancers15194687 PMID 37835381
    Consulter

  • Real-world results of autologous stem cell transplantation in newly diagnosed multiple myeloma: a report from the Canadian Myeloma Research Group database

    Julie Côté , Richard LeBlanc , Hira Mian, Michael P. Chu, Arleigh McCurdy, Esther Masih-Khan, Jiandong Su, Victor H. Jimenez-Zepeda, Kevin Song, Martha Louzada, Darrell White, Michael Sebag, Anthony Reiman, Julie Stakiw, Rami Kotb, Debra Bergstrom, Muhammad Aslam, Rayan Kaedbey , Christopher P. Venner, Engin Gul, Donna Reece
    DOI 10.1038/s41408-023-00905-8 PMID 37669949
    Consulter

  • Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis

    Arleigh McCurdy, Hira Mian , Richard LeBlanc , Victor H Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey , Engin Gul, Donna Reece, Christopher P Venner
    DOI 10.1038/s41408-023-00888-6 PMID 37635183
    Consulter

  • Outcome of carfilzomib/pomalidomide-based regimens after daratumumab-based treatment in relapsed multiple myeloma: A Canadian Myeloma Research Group Database analysis

    Richard LeBlanc , Hira Mian, Donna Reece, Jiandong Su, Esther Masih-Khan, Michael Chu, Victor Jimenez-Zepeda, Michael Sebag, Kevin Song, Martha Louzada, Rami Kotb, Alissa Visram, Darrell White, Julie Stakiw, Antony Reiman, Muhammad Aslam , Debra Bergstrom, Rayan Kaedbey, Engin Gul, Christopher Venner
    DOI 10.1111/ejh.14082 PMID 37574220
    Consulter

  • A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma

    Julie Stakiw, Shruthi Kodad , Richard LeBlanc , Michael Sebag, Annette E Hay, Vishal Kukreti, Julie Côté, Fernando Camacho, Molei Fu, Engin Gul, Donna Reece
    DOI 10.1016/j.clml.2023.03.006 PMID 37127473
    Consulter

  • Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis

    Arleigh McCurdy, Hira Mian , Richard LeBlanc , Victor H. Jimenez-Zepeda, Jiandong Su, Esther Masih-Khan, Alissa Visram, Martha Louzada, Kevin Song, Darrell White, Michael Sebag , Julie Stakiw, Anthony Reiman, Muhammad Aslam, Debra Bergstrom, Rami Kotb, Rayan Kaedbey, Engin Gul, Donna Reece, Christopher P. Venner
    DOI 10.1038/s41408-023-00883-x PMID 37474492
    Consulter

  • First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium

    Julie Côté, Rami Kotb, Debra J Bergstrom , Richard LeBlanc , Hira S Mian, Ibraheem Othman, Martha L Louzada
    DOI 10.1016/j.clml.2023.01.016 PMID 36925389
    Consulter

  • Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes

    Mégane Tanguay, Christophe Dagenais , Richard LeBlanc , Imran Ahmad , Jean-Sébastien Claveau , Jean Roy
    Consulter

  • Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study

    Alexander Lesokhin , Richard LeBlanc , Meletios A. Dimopoulos, Marcelo Capra, Carmelo Carlo-Stella, Lionel Karlin, Jean-Francois Castilloux, Peter Forsberg, Gurdeep Parmar, Axel Tosikyan, Ludek Pour, Vincent Ribrag, Rossella Ribolla, Al-Ola Abdallah , Nadia Le Roux, Liyan Dong, Helgi van de Velde, Laurent Mayrargue, Lucie Lépine, Sandrine Macé, Philippe Moreau
    DOI 10.1002/cam4.5753 PMID 36866838
    Consulter

  • Real-world data on lenalidomide dosing and outcomes in patients newly diagnosed with multiple myeloma: Results from the Canadian Myeloma Research Group Database

    Hira Mian , Richard LeBlanc , Martha Louzada, Esther Masih-Khan, Arleigh McCurdy, Christopher P. Venner, Julie Stakiw, Moustafa Kardjadj, Victor H. Jimenez-Zepeda, Michael Sebag, Darrell White, Muhammad Aslam, Kevin Song, Anthony Reiman, Rami Kotb, Engin Gul, Donna Reece
    DOI 10.1002/cam4.5245 PMID 36161712
    Consulter

  • Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD

    Jean-Sébastien Claveau , Richard LeBlanc , Imran Ahmad , Jean-Sébastien Delisle , Sandra Cohen , Thomas Kiss , Nadia Bambace , Léa Bernard , Sylvie Lachance , Denis-Claude Roy , Guy Sauvageau , Olivier Veilleux , Jean Roy
    DOI 10.1016/j.jtct.2022.10.022 PMID 36334654
    Consulter

  • Elotuzumab Plus Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Final Overall Survival Analysis From the Randomized Phase II ELOQUENT-3 Trial

    Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu , Richard LeBlanc , Kenshi Suzuki, Marc S Raab, Paul G Richardson, Mihaela Popa McKiver, Ying-Ming Jou, David Yao, Prianka Das, Jesús San-Miguel
    DOI 10.1200/JCO.21.02815 PMID 35960908
    Consulter

  • Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment

    Muhamed Baljevic, Cristina Gasparetto, Gary J Schiller, Sascha A Tuchman, Natalie S Callander, Suzanne Lentzsch, Jorge Monge, Rami Kotb, Nizar J Bahlis, Darrell White, Christine I Chen, Heather J Sutherland, Sumit Madan , Richard LeBlanc , Michael Sebag, Christopher P Venner, William I Bensinger, Noa Biran, Andrew DeCastro, Dane R Van Domelen, Chris Zhang, Jatin J Shah, Sharon Shacham, Michael G Kauffman, Ohad S Bentur, Brea Lipe
    DOI 10.1002/jha2.572 PMID 36467792
    Consulter

  • Carfilzomib usage patterns and outcomes in patients with relapsed multiple myeloma: A multi-institutional report from the Canadian Myeloma Research Group (CMRG) Database

    Arleigh McCurdy, Martha Louzada, Christopher P Venner, Alissa Visram, Esther Masih-Khan, Moustafa Kardjadj, Victor H Jimenez-Zepeda , Richard LeBlanc , Michael Sebag, Kevin Song, Darrell White, Hira Mian, Julie Stakiw, Anthony Reiman, Muhammad Aslam, Rami Kotb, Engin Gul, Donna Reece
    DOI 10.1002/jha2.559 PMID 36467802
    Consulter

  • Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database

    Hira Mian, Donna Reece, Esther Masih-Khan, Arleigh McCurdy, Moustafa Kardjadj, Victor H Jimenez-Zepeda, Kevin Song, Martha Louzada , Richard LeBlanc , Michael Sebag, Darrell White, Julie Stakiw, Anthony Reiman, Rami Kotb, Muhammad Aslam, Engin Gul, Christopher P Venner
    DOI 10.1016/j.clml.2022.03.002 PMID 35379589
    Consulter

  • Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis

    Marcelo Capra Thomas Martin Philippe Moreau Ross Baker Ludek Pour Chang-Ki Min Xavier Leleu Mohamad Mohty Marta Reinoso Segura Mehmet Turgut , Richard LeBlanc , Marie-Laure Risse Laure Malinge Sandrine Schwab Meletios Dimopoulos
    DOI 10.3324/haematol.2021.279229 PMID 34647444
    Consulter

  • Outcomes of daratumumab in the treatment of multiple myeloma: A retrospective cohort study from the Canadian Myeloma Research Group Database

    Richard LeBlanc , Hira Mian, Donna Reece, Esther Masih-Khan, Moustafa Kardjadj, Victor H. Jimenez-Zepeda, Arleigh McCurdy, Kevin Song, Michael Sebag, Martha Louzada, Darrell White, Julie Stakiw, Rami Kotb, Anthony Reiman, Muhammad Aslam, Engin Gul, Christopher P. Venner
    DOI 10.1111/bjh.18172 PMID 35383886
    Consulter

  • Sequential Use of Carfilzomib and Pomalidomide in Relapsed Multiple Myeloma: A Report from the Canadian Myeloma Research Group (CMRG) Database

    Arleigh McCurdy, Christopher P Venner, Esther Masih-Khan, Martha Louzada , Richard LeBlanc , Michael Sebag, Kevin Song, Victor H Jimenez-Zepeda, Rami Kotb, Moustafa Kardjadj, Hira Mian, Darrell White, Julie Stakiw, Muhammad Aslam, Anthony Reiman, Engin Gul, Donna Reece
    DOI 10.3390/curroncol29030132 PMID 35323332
    Consulter

  • Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis

    Hira Mian, Christine Eisfeld, Christopher P Venner, Esther Masih-Khan, Moustafa Kardjadj, Victor H Jimenez-Zepeda, Cyrus Khandanpour, Georg Lenz, Arleigh McCurdy, Michael Sebag, Kevin Song , Richard LeBlanc , Darrell White, Julie Stakiw, Anthony Reiman, Martha Louzada, Muhammad Aslam, Rami Kotb, Engin Gul, Donna Reece
    DOI 10.3389/fonc.2022.826342 PMID 35251992
    Consulter

  • Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma

    Jean-Sébastien Claveau , Sophie Savary Bélanger , Imran Ahmad , Jean-Sébastien Delisle , Vincent De Guire , Jean Roy , Richard LeBlanc
    DOI 10.1038/s41408-021-00600-6 PMID 34987163
    Consulter

  • Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium

    Richard LeBlanc , Debra J Bergstrom, Julie Côté, Rami Kotb, Martha L Louzada, Heather J Sutherland
    DOI 10.1016/j.clml.2021.07.028 PMID 34456159
    Consulter

  • Outcomes in newly diagnosed young or high-risk myeloma patients receiving tandem autologous/allogeneic transplant followed by bortezomib maintenance: a phase II study

    Richard LeBlanc , Imran Ahmad , Rafik Terra, Jean-Samuel Boudreault, David Ogez, Kristopher Lamore , Jean-Sébastien Delisle , Nadia Bambace , Léa Bernard , Sandra Cohen , Thomas Kiss , Sylvie Lachance , Séverine Landais, Émilie Lemieux-Blanchard , Guy Sauvageau , Michael Sebag , Denis-Claude Roy , Jean Roy
    DOI 10.1038/s41409-021-01532-2 PMID 34845367
    Consulter

  • Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients

    Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Muhamed Baljevic, Suzanne Lentzsch, Adriana C. Rossi, Rami Kotb, Darrell White, Nizar J. Bahlis, Christine I. Chen, Heather J. Sutherland, Sumit Madan, , Richard LeBlanc , Michael Sebag, Christopher P. Venner, William I. Bensinger, Noa Biran, Sonia Ammu, Osnat Ben-Shahar, Andrew DeCastro , Dane Van Domelen, Tianjun Zhou, Chris Zhang, Ohad S. Bentur, Jatin Shah, Sharon Shacham, Michael Kauffman, Brea Lipe
    DOI 10.1038/s41416-021-01608-2 PMID 34802051
    Consulter

  • Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada

    Donna E. Reece, Esther Masih-Khan, Ehetu G. Atenafu, Victor H. Jimenez-Zepeda, Arleigh McCurdy, Kevin Song , Richard LeBlanc , Michael Sebag, Darrell White, Hannah Cherniawsky, Anthony Reiman, Julie Stakiw, Martha L. Louzada, Rami Kotb, Muhammad Aslam, Engin Gul, Christopher P. Venner
    DOI 10.1111/ejh.13678 PMID 34129703
    Consulter

  • A phase-1 trial of linsitinib (OSI-906) in combination with bortezomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

    Sahar Khan , Richard LeBlanc , Martin Gyger, Darrell White, Johnathan Kaufman, Andrzej Jazubowiak, Engin Gul, Harminder Paul, Lisa W Le, Anthea Lau, Zhihua Li, Suzanne Trudel
    DOI 10.1080/10428194.2021.1876864 PMID 33509009
    Consulter

  • The survival impact of maintenance lenalidomide: an analysis of real-world data from the Canadian Myeloma Research Group national database

    Hannah M. Cherniawsky Vishal Kukreti Donna Reece Esther Masih-Khan Arleigh McCurdy Victor H. Jimenez-Zepeda Michael Sebag Kevin Song Darrell White Julie Stakiw , Richard LeBlanc , Anthony Reiman Muhammad Aslam Martha Louzada Rami Kotb Engin Gul Eshetu Atenafu Christopher P. Venner
    DOI 10.3324/haematol.2020.259093 PMID 33054120
    Consulter

  • Real-world outcomes with bortezomib-containing regimens and lenalidomide plus dexamethasone for the treatment of transplant-ineligible multiple myeloma: a multi-institutional report from the Canadian Myeloma Research Group database

    Victor H. Jimenez-Zepeda, Christopher Venner, Arleigh McCurdy, Esther Masih-Khan, Eshetu G. Atenafu, Michael Sebag, Julie Stakiw, Kevin Song , Richard LeBlanc , Tony Reiman, Martha Louzada, Rami Kotb, Engin Gul, Donna Reece
    DOI 10.1111/bjh.17350 PMID 33559897
    Consulter

  • Weekly carfilzomib plus cyclophosphamide and dexamethasone in the treatment of relapsed/refractory multiple myeloma: Final results from the MCRN-003/MYX.1 single arm phase II trial

    Christopher P. Venner , Richard LeBlanc , Irwindeep Sandhu, Darrell White, Andrew R. Belch, Donna E. Reece, Christine Chen, Sean Dolan, Marc Lalancette, Martha Louzada, Andrea Kew, Arleigh McCurdy, Bethany Monteith, Tony Reiman, Gail McDonald, Max Sherry, Engin Gul, Bingshu Chen, Annette E. Hay
    DOI 10.1002/ajh.26147 PMID 33650179
    Consulter

  • The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma

    Hannah M. Cherniawsky, Vishal Kukreti, Donna Reece, Esther Masih-Khan, Arleigh McCurdy, Victor H. Jimenez-Zepeda, Michael Sebag, Kevin Song, Darrell White, Julie Stakiw , Richard LeBlanc , Anthony Reiman, Martha Louzada, Muhammad Aslam, Rami Kotb, Engin Gul, Eshetu Atenafu, Christopher P. Venner
    DOI 10.1111/ejh.13596 PMID 33539037
    Consulter

  • Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma

    Cristina Gasparetto, Suzanne Lentzsch, Gary Schiller, Natalie Callander, Sascha Tuchman, Christine Chen, Darrell White, Rami Kotb, Heather Sutherland, Michael Sebag, Muhamed Baljevic, William Bensinger , Richard LeBlanc , Chris Venner, Nizar Bahlis, Adriana Rossi, Noa Biran, Heidi Sheehan, Jean-Richard Saint-Martin, Dane Van Domelen, Kazuharu Kai, Jatin Shah, Sharon Shacham, Michael Kauffman, Brea Lipe
    DOI 10.1002/jha2.122 PMID 35846104
    Consulter

  • Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only

    Richard LeBlanc , Jean-Sébastien Claveau , Imran Ahmad , Jean-Sébastien Delisle , Nadia M Bambace , Léa Bernard , Sandra Cohen , Thomas Kiss , Sylvie Lachance , Séverine Landais , Denis-Claude Roy , Guy Sauvageau , Jean Roy
    DOI 10.1111/ctr.14099 PMID 32981146
    Consulter

  • Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium

    Debra J Bergstrom, Rami Kotb, Martha L Louzada, Heather J Sutherland, Sofia Tavoularis, Christopher P Venner; Myeloma Canada Research Network Consensus Guideline Consortium , Richard LeBlanc , Jean Roy
    DOI 10.1016/j.clml.2020.01.017 PMID 32249195
    Consulter

  • Clinicopathologic predictors of renal outcomes in light chain cast nephropathy: a multicenter retrospective study

    Virginie Royal, Nelson Leung, Stéphan Troyanov, Samih H. Nasr, Laure Écotière , Richard LeBlanc , Benjamin A. Adam, Andrea Angioi, Mariam P. Alexander, Anna Maria Asunis, Antonella Barreca, Paola Bianco, Camille Cohen, Maria E. Drosou, Huma Fatima, Roberta Fenoglio, François Gougeon, Jean-Michel Goujon, Guillermo A. Herrera, Bertrand Knebelmann , Nicola Lepori, Francesca Maletta, Rita Manso, Shveta S. Motwani, Antonello Pani, Marion Rabant, Helmut G. Rennke, Dario Rocatello, Frida Rosenblum, Paul W. Sanders, Afonso Santos , Karina Soto, Banu Sis, Guy Touchard, Christopher P. Venner, Frank Bridoux for the International Kidney and Monoclonal Gammopathy Research Group
    DOI 10.1182/blood.2019003807 PMID 32160635
    Consulter

  • Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib

    Paul G Richardson, Arnon Nagler, Dina Ben-Yehuda, Ashraf Badros, Parameswaran N Hari, Roman Hajek, Ivan Spicka, Hakan Kaya , Richard LeBlanc , Sung-Soo Yoon, Kihyun Kim, Joaquin Martinez-Lopez, Moshe Mittelman, Ofer Shpilberg, Paul Blake , Teru Hideshima, Kathleen Colson, Jacob P Laubach, Irene M Ghobrial, Merav Leiba, Moshe E Gatt, Peter Sportelli, Michael Chen, Kenneth C Anderson
    DOI 10.1002/jha2.4 PMID 35847734
    Consulter

  • Updates from the 2019 American Society of Clinical Oncology and European Hematology Association annual meetings: a Canadian perspective on high-risk cytogenetics in multiple myeloma

    Richard LeBlanc , K Song, D White, A Christofides, S Doucette
    DOI 10.3747/co.26.5565 PMID 31548829
    Consulter

  • Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial

    Saad Zafar Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo, Robert M Rifkin, Habte Aragaw Yimer , Richard LeBlanc , Naoki Takezako, Robert Donald McCroskey, Andrew Boon Ming Lim, Kenshi Suzuki, Hiroshi Kosugi, George Grigoriadis, Irit Avivi, Thierry Facon, Sundar Jagannath, Sagar Lonial , Razi Uddin Ghori, Mohammed Z H Farooqui, Patricia Marinello, Jesus San-Miguel; KEYNOTE-185 Investigators
    DOI 10.1016/S2352-3026(19)30109-7 PMID 31327689
    Consulter

  • Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma

    Meletios A Dimopoulos, Dominik Dytfeld, Sebastian Grosicki, Philippe Moreau, Naoki Takezako, Mitsuo Hori, Xavier Leleu , Richard LeBlanc , Kenshi Suzuki, Marc S Raab, Paul G Richardson, Mihaela Popa McKiver, Ying-Ming Jou, Suresh G Shelat, Michael Robbins, Brian Rafferty, Jesús San-Miguel
    DOI 10.1056/NEJMoa1805762 PMID 30403938
    Consulter

  • Cerebral adenovirus endotheliitis presenting as posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation

    Jean-Sébastien Claveau , Richard LeBlanc , Imran Ahmad , J Ferreira, A-A Pistono, Nadia M Bambace , Léa Bernard , Sandra Cohen , Jean-Sébastien Delisle , Thomas Kiss , Sylvie Lachance , Jean Roy
    DOI 10.1038/bmt.2017.154 PMID 28692025
    Consulter

  • Updated Outcomes and Impact of Age With Lenalidomide and Low-Dose Dexamethasone or Melphalan, Prednisone, and Thalidomide in the Randomized, Phase III FIRST Trial

    Cyrille Hulin, Andrew Belch, Chaim Shustik, Maria Teresa Petrucci, Ulrich Dührsen, Jin Lu, Kevin Song, Philippe Rodon, Brigitte Pégourié, Laurent Garderet, Hannah Hunter, Isabelle Azais, Richard Eek, Heinz Gisslinger, Margaret Macro, Shaker Dakhil , Cristina Goncalves , Richard LeBlanc , Ken Romeril, Bruno Royer, Chantal Doyen, Xavier Leleu, Fritz Offner, Nicolas Leupin, Vanessa Houck, Guang Chen, Annette Ervin-Haynes, Meletios A. Dimopoulos, Thierry Facon
    DOI 10.1200/JCO.2016.66.7295 PMID 27325857
    Consulter

  • Favorable long-term outcome of patients with multiple myeloma using a frontline tandem approach with autologous and non-myeloablative allogeneic transplantation

    Imran Ahmad , Richard LeBlanc , Sandra Cohen , Sylvie Lachance , Thomas Kiss , Guy Sauvageau , Denis-Claude Roy , Lambert Busque , Jean-Sébastien Delisle , Nadia M Bambace , Léa Bernard , W Sabry , Jean Roy
    DOI 10.1038/bmt.2015.319 PMID 26691426
    Consulter

  • Canadian cost analysis comparing maintenance therapy with bortezomib versus lenalidomide for patients with multiple myeloma post autologous stem cell transplant

    Richard LeBlanc , S Hollmann, J Tay
    PMID 27337740
    Consulter

  • Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

    Sagar Lonial, Brendan M Weiss, Saad Z Usmani, Seema Singhal, Ajai Chari, Nizar J Bahlis, Andrew Belch, Amrita Krishnan, Robert A Vescio, Maria Victoria Mateos , Amitabha Mazumder, Robert Z Orlowski, Heather J Sutherland, Joan Bladé, Emma C Scott, Albert Oriol, Jesus Berdeja, Mecide Gharibo, Don A Stevens , Richard LeBlanc , Michael Sebag, Natalie Callander, Andrzej Jakubowiak, Darrell White, Javier de la Rubia, Paul G Richardson, Steen Lisby, Huaibao Feng, Clarissa M Uhlar, Imran Khan, Tahamtan Ahmadi, Peter M Voorhees
    DOI 10.1016/S0140-6736(15)01120-4 PMID 26778538
    Consulter

  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    Jesús F San-Miguel, Vânia T M Hungria, Sung-Soo Yoon, Meral Beksac, Meletios Athanasios Dimopoulos, Ashraf Elghandour, Wieslaw Wiktor Jedrzejczak , Andreas Günther, Thanyaphong Na Nakorn, Noppadol Siritanaratkul, Paolo Corradini, Suporn Chuncharunee, Je-Jung Lee, Robert L Schlossman, Tatiana Shelekhova, Kwee Yong, Daryl Tan, Tontanai Numbenjapon, Jamie D Cavenagh, Jian Hou , Richard LeBlanc , Hareth Nahi, Lugui Qiu, Hans Salwender, Stefano Pulini, Philippe Moreau, Krzysztof Warzocha, Darrell White, Joan Bladé, WenMing Chen , Javier de la Rubia, Peter Gimsing, Sagar Lonial, Jonathan L Kaufman, Enrique M Ocio, Ljupco Veskovski, Sang Kyun Sohn, Ming-Chung Wang, Jae Hoon Lee , Hermann Einsele, Monika Sopala, Claudia Corrado, Bourras-Rezki Bengoudifa, Florence Binlich, Paul G Richardson
    DOI 10.1016/S1470-2045(14)70440-1 PMID 25242045
    Consulter